TrialsgrambetaRCTs are beautiful

REMAP-CAP / ATTACC / ACTIV-4a

2021

Therapeutic-Dose Heparin in COVID-19

In hospitalised COVID-19 patients across three coordinated platforms, therapeutic-dose heparin improved organ-support-free days in moderate illness but not in critically ill patients.

Result

Primary endpoint: Organ-support-free days at 21 days

Moderate-illness benefit; critically ill futility, possible harm.

Original publication
Subtopic
Anticoagulation
Design
Coordinated multi-platform RCT
Enrolled
3,398 patients
Relevance
Important: one of several pillars.
Source
ATTACC, ACTIV-4a, REMAP-CAP Investigators. N Engl J Med. 2021;385(9):790-802 and 385(9):777-789.doi 10.1056/NEJMoa2105911

Discussion & critique

Defined the moderate-vs-severe split for therapeutic anticoagulation in COVID-19.

Discussed in podcasts